DEPARTMENT OF BIOLOGICAL PRODUCTION (BP)


Biological Production Banner

Main activities of the Institute include production and supply of important veterinary biologicals required for prophylaxis of livestock and poultry diseases and also to ensure complete health coverage by prompt diagnosis of diseases on the face of an outbreak. Biological production division is producing many viral vaccines, bacterial vaccines and diagnostic antigens.

The details of vaccines produced are as mentioned below:

AEROBIC SECTION
  • Haemorrhagic Septicaemia
  • Anthrax
ANAEROBIC SECTION
  • Black Quarter
  • Enterotoxaemia
  • Rabies
  • Ppr
  • Sheep Pox
  • Ranikhet (F and R2B)
  • Fowl & Pigeon Pox
  • Kfd
  • Pullorum colour antigen
  • Pullorum plain antigen
  • Brucella abortus plain antigen
  • Brucella rose bengal antigen
  • Brucella milk ring antigen
  • Blue Tongue Vaccine
  • Classical Swine Fever Vaccine
  • Duck Cholera Vaccine
  • Mycoplasma Antigen

 

Achievements of Biological production

During the year 2013-14 & 2014-15 Rs. 830.72 lakh & Rs 900 lakh worth vaccines were produced and supplied to the State Government.

  • Production of Pentavalent BT vaccine with a different adjuvant is under progress.
  • Swine fever live cell culture vaccine has been granted NOC from GOI for producing the vaccine and only few formalities are left for grant of permanent license. Trials conducted revealed satisfactory results and its first tissue culture adapted Swine fever vaccine in the country.
  • Development of LPB- ELISA and iELISA for diagnosis and sero- surveillance of CSF is under progress.
  • Dose reduction of HS & BQ vaccine is under progress.
  • HS & BQ combined vaccine development is under way.
  • Completely GMP compliance production facility with state of the art fully automated fermenters is completely ready and is due for inauguration.

Motto of Biological production division

  • Total health coverage of livestock of the state
  • Production of quality vaccines to cover the livestock population and to create "HERD IMMUNITY" ( 100 %, or atleast 80%)
  • Latest technology
  • Less human intervention as per GMP norms( Schedule –M)
  • Develop newer vaccines and diagnostics
  • Develop newer technologies to improve the quality and cost effectiveness